Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy For Advanced Colorectal Cancer And High Risk Of Developing Colorectal Peritoneal Carcinomatosis:Short-term Efficacy And Security Report

Objective:To evaluate the short-term efficacy and security of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for advanced colorectal cancer and high risk of developing colorectal peritoneal carcinomatosis.To provide evidence of treatment for these people.Methods:21patients of advanced colorectal cancer and high risk of developing colorectal peritoneal carcinomatosisundergoing cytoreductive surgery andhyperthermic intraperitoneal chemotherapy were collected from2014/4to2015/3. Postoperative recovery, safety index and quality of life were evaluated. Results:We collected21patients, post-operation hospital stay of patients of advanced colorectal cancer is between10days to15days, post-operation hospital stay of one patient of high risk of developing colorectal peritoneal carcinomatosis is less than10days, the other is more than50days. Serious adverse effect are hypoalbuminemia (n=1), neutropenia (n=1), hyperbilirubinernia(n=1), hyperglycemia(n=1), hypocalcemia(n=1), Thrombotic events(n=1), Gastrointestinal obstruction=1), anastomotic fistula(n=2). The overall morbidity rate is23.8%and mortality is0%. The qualitity of life of12patients is different between preopertion and post operation, which are physical function (p=0.008), role function (p=0.035), dry mouth (p=0.022).9patients are lost to follow-up.Conclusions:The morbidity and mortality rate of CRS/HIPEC is relatively low. The short-term quality of life may fall, but the result is acceptable. CRS/HIPEC treating advanced colorectal cancer and high risk of developing colorectal peritoneal carcinomatosishas demonstrated short-term efficacy and security. It provides evidence of treatment for these people.